title: De novo cancer in cyclosporine-treated and non-cyclosporine-treated adult primary renal allograft recipients.
abstract: We compared the incidence of de novo tumors developing in 1165 primary adult renal allograft recipients treated with azathioprine (AZA)-prednisone (Pred)-antilymphocyte globulin (ALG) (CONV group) with that in 722 patients receiving cyclosporine (CSA) as part of double (CSA-Pred), triple (CSA-Pred-AZA), or quadruple-therapy (CSA-Pred-AZA-ALG) protocols. Mean +/- SD follow-up was 9.5 +/- 6.4 years for the CONV group and 6.2 +/- 2.7 years for the CSA group. Overall, 124 patients (10.6%) in the CONV group and 34 patients (4.7%) in the CSA group developed malignancies, with nonmelanoma skin cancers and lymphomas comprising 55% and 13% of cancers in the CONV group and 65% and 3% of cancers in the CSA group, respectively. There were no significant differences in overall cancer (p = 0.41) or skin cancer (p = 0.97) incidence between non-CSA-treated and CSA-treated patients by Kaplan-Meier life-table analysis; however, CONV-treated patients demonstrated a higher incidence of lymphoma (p = 0.05). The mean (+/- SD) time to overall and skin cancer occurrence was significantly shorter in the CSA group: 37 +/- 22 versus 90 +/- 52 months (p < 0.001) and 40 +/- 24 versus 92 +/- 52 months, respectively. When the Cox Proportional Hazard Model was utilized to assess the relative importance of age, diabetic status, donor source, sex, and immunosuppressive regimen in determining cancer development, age > or = 50 years and nondiabetic status were significant independent prognostic indicators, while immunosuppressive regimen was not. Graft and patient survival were significantly greater in CONV-treated patients developing cancer than in those who did not.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Surgery, University of Minnesota, Minneapolis.
authors.forename: S A
authors.initials: SA
authors.lastname: Gruber
authors.forename: K
authors.initials: K
authors.lastname: Gillingham
authors.forename: R B
authors.initials: RB
authors.lastname: Sothern
authors.forename: E
authors.initials: E
authors.lastname: Stephanian
authors.forename: A J
authors.initials: AJ
authors.lastname: Matas
authors.forename: D L
authors.initials: DL
authors.lastname: Dunn
mesh_terms: D000328:Adult; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006085:Graft Survival; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015994:Incidence; D016030:Kidney Transplantation; D015993:Life Tables; D008223:Lymphoma / Q000453:epidemiology*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000453:epidemiology*; D016016:Proportional Hazards Models; D012307:Risk Factors; D012878:Skin Neoplasms / Q000453:epidemiology*; D013997:Time Factors
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine